News
1 In 2017, Novo Nordisk introduced semaglutide (Ozempic), a long-acting GLP-1 RA used to improve glycemic control, and later approved in 2021 ... Limitations of Ophthalmic Research Into GLP-1 RA Use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback